Details for 2022175210
Up to date per 01.04.2026
Actions
Details for 2022175210
Granted/Registered
European Patent
05.10.2022 A
01.03.2023 B1
31.08.2010
US
37883110 P
A61K 9/127 20060101AFI20220714BHEP
Owner
GlaxoSmithKline Biologicals SARue de l'Institut 89 1330 RixensartBE
Representative
Representative
Schwarz & Partner Patentanwälte GmbHWipplingerstraße 301010 WienAT
Inventor
GEALL, Andrew Emeryville, CA 94662-8097US
VERMA, Ayush Emeryville, CA 94662-8097US
Information about Fees